Septerna Executive Sells Shares, Reduces Holdings by 13.46%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 40 minutes ago
0mins
Source: Fool
- Transaction Overview: According to an SEC Form 4 filing, Septerna's SVP Daniel D. Long exercised and immediately sold 15,000 shares of Common Stock on June 22, 2026, with a transaction value of approximately $533,000, indicating executive liquidity management.
- Change in Holdings: This transaction reduced Long's direct holdings from 111,412 shares to 96,412 shares, a decrease of 13.46%, while indirect holdings remained at zero, reflecting a strategic adjustment in executive stock management.
- Continued Equity Exposure: Post-transaction, Long retains 96,412 shares of Common Stock and approximately 36,000 unexercised stock options, indicating ongoing confidence in Septerna despite the reduction in direct holdings.
- Company Background: Septerna is a clinical-stage biotechnology firm focused on developing oral small-molecule therapies targeting G protein-coupled receptors, currently collaborating with Novo Nordisk to develop treatment candidates for obesity and type 2 diabetes, showcasing its potential in addressing complex disease treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEPN
Wall Street analysts forecast SEPN stock price to fall
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.340
Low
25.00
Averages
33.14
High
43.00
Current: 37.340
Low
25.00
Averages
33.14
High
43.00
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Septerna Executive Sells Shares, Reduces Holdings by 13.46%
- Transaction Overview: According to an SEC Form 4 filing, Septerna's SVP Daniel D. Long exercised and immediately sold 15,000 shares of Common Stock on June 22, 2026, with a transaction value of approximately $533,000, indicating executive liquidity management.
- Change in Holdings: This transaction reduced Long's direct holdings from 111,412 shares to 96,412 shares, a decrease of 13.46%, while indirect holdings remained at zero, reflecting a strategic adjustment in executive stock management.
- Continued Equity Exposure: Post-transaction, Long retains 96,412 shares of Common Stock and approximately 36,000 unexercised stock options, indicating ongoing confidence in Septerna despite the reduction in direct holdings.
- Company Background: Septerna is a clinical-stage biotechnology firm focused on developing oral small-molecule therapies targeting G protein-coupled receptors, currently collaborating with Novo Nordisk to develop treatment candidates for obesity and type 2 diabetes, showcasing its potential in addressing complex disease treatments.
See More
Septerna Executive Sells Shares to Supplement Income
- Transaction Overview: On June 22, 2026, Daniel D. Long, SVP of Septerna, exercised and sold 15,000 shares of common stock for approximately $533,000 at a weighted average price of $35.51 per share, impacting 13.46% of his direct holdings and reducing his position to 96,412 shares.
- Execution Method: The transaction was executed directly through option exercise followed by immediate sale, indicating Long's direct involvement without any indirect entities, although this action does not necessarily reflect confidence in the company's future.
- Company Background and Partnerships: Septerna is a clinical-stage biotechnology firm specializing in oral small-molecule therapies targeting GPCRs, currently collaborating with Novo Nordisk to develop multiple treatment candidates for obesity and type 2 diabetes, among other cardiometabolic diseases.
- Market Performance and Analysis: While Long's stock sale may be aimed at supplementing his income, analysts note that Septerna was not included in The Motley Fool Stock Advisor's list of top investment picks, reflecting a cautious market sentiment regarding its future performance.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
Septerna, Inc. Q1 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q1 GAAP EPS of -$0.19, beating expectations by $0.25, indicating an improvement in profitability despite still being in the red.
- Significant Revenue Growth: The company achieved Q1 revenue of $26.52M, exceeding market expectations by $11.43M, reflecting strong market demand for its products or services, which could drive future growth.
- Robust Cash Reserves: As of March 31, 2026, Septerna reported cash, cash equivalents, and marketable securities totaling $522.1M, ensuring sufficient operational funding for the coming years, with expectations to last at least until 2029.
- Positive Future Outlook: With the Phase 1 readout of SEP-631, Septerna anticipates a new growth catalyst in 2026, further solidifying its market position in the biopharmaceutical sector.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Septerna Executive Sells Shares, Reduces Holdings by 13.46%
- Transaction Overview: According to an SEC Form 4 filing, Septerna's SVP Daniel D. Long exercised and immediately sold 15,000 shares of Common Stock on June 22, 2026, with a transaction value of approximately $533,000, indicating executive liquidity management.
- Change in Holdings: This transaction reduced Long's direct holdings from 111,412 shares to 96,412 shares, a decrease of 13.46%, while indirect holdings remained at zero, reflecting a strategic adjustment in executive stock management.
- Continued Equity Exposure: Post-transaction, Long retains 96,412 shares of Common Stock and approximately 36,000 unexercised stock options, indicating ongoing confidence in Septerna despite the reduction in direct holdings.
- Company Background: Septerna is a clinical-stage biotechnology firm focused on developing oral small-molecule therapies targeting G protein-coupled receptors, currently collaborating with Novo Nordisk to develop treatment candidates for obesity and type 2 diabetes, showcasing its potential in addressing complex disease treatments.
See More
Septerna Executive Sells Shares to Supplement Income
- Transaction Overview: On June 22, 2026, Daniel D. Long, SVP of Septerna, exercised and sold 15,000 shares of common stock for approximately $533,000 at a weighted average price of $35.51 per share, impacting 13.46% of his direct holdings and reducing his position to 96,412 shares.
- Execution Method: The transaction was executed directly through option exercise followed by immediate sale, indicating Long's direct involvement without any indirect entities, although this action does not necessarily reflect confidence in the company's future.
- Company Background and Partnerships: Septerna is a clinical-stage biotechnology firm specializing in oral small-molecule therapies targeting GPCRs, currently collaborating with Novo Nordisk to develop multiple treatment candidates for obesity and type 2 diabetes, among other cardiometabolic diseases.
- Market Performance and Analysis: While Long's stock sale may be aimed at supplementing his income, analysts note that Septerna was not included in The Motley Fool Stock Advisor's list of top investment picks, reflecting a cautious market sentiment regarding its future performance.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
Septerna, Inc. Q1 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q1 GAAP EPS of -$0.19, beating expectations by $0.25, indicating an improvement in profitability despite still being in the red.
- Significant Revenue Growth: The company achieved Q1 revenue of $26.52M, exceeding market expectations by $11.43M, reflecting strong market demand for its products or services, which could drive future growth.
- Robust Cash Reserves: As of March 31, 2026, Septerna reported cash, cash equivalents, and marketable securities totaling $522.1M, ensuring sufficient operational funding for the coming years, with expectations to last at least until 2029.
- Positive Future Outlook: With the Phase 1 readout of SEP-631, Septerna anticipates a new growth catalyst in 2026, further solidifying its market position in the biopharmaceutical sector.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
